BioSpace News Archive

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two oral presentations and three poster presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology (ASTRO)

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), announces today that CEO Donal Schmidt will present a corporate overview at the 14th Annual LD Micro Main Event Conference which is being held at the Luxe Sunset Bel-Air in Los Angeles from October 12 – 14, 2021.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (“GI”) diseases in areas of high unmet need, today announced the Company’s reconvened annual meeting of shareholders, on October 6, 2021, at 9:30 a.m. ET.

Biophytis SA announced that the Company’s previously issued audited consolidated financial statements for the fiscal years ended December 31, 2019 and 2020 and unaudited consolidated financial statements for the six month periods ended June 30, 2021 and 2020 will be restated to correct the Company’s accounting treatment of its convertible notes.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled “CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial” will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 49,625 shares of Puma common stock to six new non-executive employees.

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults.

Theseus Pharmaceuticals, Inc., a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, announced the pricing of its initial public offering of 10,000,200 shares of its common stock at a price to the public of $16.00 per share.

Cyclo Therapeutics, Inc. today announced it will participate in the 2021 Virtual Cyclodextrin Conference hosted by CycloLab, “Cyclodextrins as active ingredients in the 21st century,” taking place on October 11, 2021.